IGM Biosciences to Present at the 2024 RBCCM Global Healthcare Conference
07 Mai 2024 - 1:00PM
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage
biotechnology company creating and developing engineered IgM
antibodies, today announced that management will participate in a
fireside chat at the 2024 RBCCM Global Healthcare Conference on
Tuesday, May 14, 2024, at 2:35 p.m. EDT.
A live webcast of the event will be available on the “Events and
Presentations” page in the “Investors” section of the Company’s
website at
https://investor.igmbio.com/news-and-events/events-and-presentations.
A replay of the webcast will be archived on the Company’s website
for 90 days following the presentation.
About IGM Biosciences, Inc.IGM
Biosciences is a clinical-stage biotechnology company
committed to developing and delivering a new class of medicines to
treat patients with cancer and autoimmune and inflammatory
diseases. IGM’s pipeline of clinical and preclinical assets is
based on the IgM antibody, which has 10 binding sites compared to
conventional IgG antibodies with only 2 binding sites. IGM also has
an exclusive worldwide collaboration agreement with Sanofi to
create and develop IgM agonist antibodies against immunology and
inflammation targets. For more information, please visit
www.igmbio.com.
Contact:Argot PartnersDavid
Pitts212-600-1902igmbio@argotpartners.com
IGM Biosciences (NASDAQ:IGMS)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
IGM Biosciences (NASDAQ:IGMS)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024